A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs CRS 207 (Primary) ; Cisplatin; Cyclophosphamide; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Aduro BioTech
- 28 Aug 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 28 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 25 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History